Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 102kWORD 17k
1 December 2016
Question for written answer E-009119-16
to the Commission
Rule 130
Karol Karski (ECR)

 Subject:  Antimicrobial resistance
 Answer in writing 

According to experts, some 25 000 people die each year in the Member States as a result of antimicrobial resistance (AMR). The excessive or inappropriate use of antimicrobial treatments is making various strands of bacteria resistant to them. In an effort to tackle the issue, the Commission has drawn up an antimicrobial resistance action plan, which is to be launched in 2017.

Its most important initiative will be to support national anti-AMR programmes in the areas of medicine and veterinary medicine, the training of specialists and the raising of public awareness of the risks of AMR. The Commission has announced that it will be funding research into new antibiotics, rapid diagnostic tests, vaccines and medicines that could offer an alternative to antibiotics.

The plan also involves closer cooperation between EU health agencies such as the European Medicines Agency, the European Centre for Disease Prevention and Control and pharmaceutical manufacturers. The Commission’s previous programme, which was carried out between 2011 and 2016, focused primarily on limiting the excessive use of antibiotics in agriculture and for veterinary purposes.

1. From what funds will the AMR action plan be financed?2. What has been the outcome of the Commission’s 2011-2016 programme?3. How much money is the Commission planning to allocate to individual Member States to help them tackle AMR in 2017?

Original language of question: PL 
Legal notice